Pulse Biosciences Inc

Pulse Biosciences is a bioelectric medicine company developing proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology that delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent non-cellular tissue. The company's primary focus is developing its nPulse technology for the treatment of atrial fibrillation (AF) through both endocardial catheter and surgical approaches. The nPulse Cardiac Catheter System is being evaluated in the NANOPULSE-AF U.S. IDE pivotal study, while the nPulse Cardiac Surgical System is being studied in the NANOCLAMP-AF pivotal trial for concomitant surgical AF ablation. Additionally, the company markets the Vybrance system for soft tissue ablation in a controlled commercial launch and is conducting clinical studies for benign thyroid nodules (PRECISE-BTN) and papillary thyroid microcarcinoma in collaboration with MD Anderson Cancer Center. The company is currently pre-revenue at scale, generating limited product revenue from its Vybrance system while investing heavily in clinical development across its cardiac and soft tissue programs. Updated Aug 6, 2026